Human LYVE-1 Antibody
R&D Systems, part of Bio-Techne | Catalog # AF2089
Key Product Details
Validated by
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Ser24-Thr238
Accession # Q9Y5Y7
Specificity
Clonality
Host
Isotype
Endotoxin Level
Scientific Data Images for Human LYVE-1 Antibody
LYVE-1 in Human Tonsil.
LYVE-1 was detected in immersion fixed paraffin-embedded sections of human tonsil using 15 µg/mL Goat Anti-Human LYVE-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2089) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.Detection of Human LYVE-1 by Western Blot.
Western blot shows lysates of human liver and spleen tissue. PVDF membrane was probed with 0.25-1 µg/mL of Goat Anti-Human LYVE-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2089) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for LYVE-1 at approximately 60 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.Detection of Human LYVE-1 by Immunocytochemistry/Immunofluorescence
Overview of Multi-dimensional Microscopic Molecular Profiling (MMMP).The overall MMMP approach is depicted using an example tissue section from normal human duodenum (sample #1.9.7). (a) Slides were subjected to repeated cycles of staining and imaging with fluorescent primary antibodies and DAPI. At the end of each cycle, fluorescent signal was removed by a chemical bleaching process, and slides were again imaged, before proceeding to the next round of this iterative procedure. After the final antibody stain (#15 Sma), slides were analyzed with a series of histochemical stains. (b) A set of tiling images spanning each tissue section was initially generated by the microscope system. The tiling images were then computationally ‘stitched’ together to produce a single image per staining cycle for each sample. (c) Image registration was performed to align images from the same tissue section across cycles. Mean intensities of the DAPI signal from all immuno-fluorescence images are shown from before (Unregistered) and after (Registered) the image registration procedure was completed. (d) Following registration, signal intensities from the relevant channels for each image (columns) in the MMMP series were extracted for each pixel (rows) within the tissue section and compiled into a large data matrix of in situ molecular profiles. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0128975), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human LYVE-1 Antibody
Blockade of Receptor-ligand Interaction
Immunohistochemistry
Sample: Immersion fixed paraffin-embedded sections of human tonsil
Western Blot
Sample: Human liver and spleen tissue
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: LYVE-1
LYVE-1 is primarily expressed on both the luminal and abluminal surfaces of lymphatic vessels (4, 5). In addition, LYVE-1 is also present in normal hepatic blood sinusoidal endothelial cells (6). LYVE-1 mediates the endocytosis of HA and may transport HA from tissue to lymph by transcytosis, delivering HA to lymphatic capillaries for removal and degradation in the regional lymph nodes (5, 7, 8). Because of its restricted expression patterns, LYVE-1, along with other lymphatic proteins such as VEGF R3, podoplanin and the homeobox protein propero-related (Prox-1), constitute a set of markers useful for distinguishing between lymphatic and blood microvasculature (4, 5, 9-11).
References
- Knudson, C.B. and W. Knudson (1993) FASEB J. 7:1233.
- Evered, D and J. Whelan (1989) Ciba Found. Symp. 143:1.
- Laurent, T.C. and J.R.F. Fraser (1992) FASEB J. 6:2397.
- Banerji, S. et al. (1999) J. Cell Biol. 144:789.
- Prevo, R. et al. (2001) J. Biol. Chem. 276:19420.
- Jackson, D.J. et al. (2001)Trends Immunol. 22:317.
- Zhou, B. et al. (2000) J. Biol. Chem. 275:37733.
- Achen, M. et al. (1998) Proc. Natl. Acad. Sci. USA 95:548.
- Breiteneder-Gellef, S. et al. (1999) Am. J. Pathol. 154:385.
- Wiggle, J.T. and G. Oliver (1999) Cell 98:769.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional LYVE-1 Products
Product Documents for Human LYVE-1 Antibody
Product Specific Notices for Human LYVE-1 Antibody
For research use only